help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Misra, M.
Right arrow Articles by Klibanski, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Misra, M.
Right arrow Articles by Klibanski, A.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 8 3816-3822
Copyright © 2003 by The Endocrine Society

Serum Osteoprotegerin in Adolescent Girls with Anorexia Nervosa

Madhusmita Misra, Leslie A. Soyka, Karen K. Miller, David B. Herzog, Steven Grinspoon, Dave de Chen, Gregory Neubauer and Anne Klibanski

Neuroendocrine Unit (M.M., K.K.M., S.G., A.K.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; Department of Pediatrics (L.A.S.), University of Massachusetts Medical School, Worcester, Massachusetts 01655; Eating Disorders Unit (D.B.H.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; Amgen (D.D.C.), Thousand Oaks, California 91320; and General Clinical Research Center (G.N.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Anne Klibanski, M.D., Neuroendocrine Unit, Bulfinch 457, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: aklibanski{at}partners.org.

Low bone mineral density (BMD) in adolescents with anorexia nervosa (AN) is associated with a low bone turnover state. Osteoprotegerin (OPG), a cytokine that acts as a decoy receptor for receptor activator of nuclear factor-{kappa}B ligand, decreases bone resorption by inhibiting differentiation of osteoclast precursors and activation of mature osteoclasts, and by stimulating osteoclast apoptosis. We compared OPG levels in 43 adolescent girls with AN with 38 controls and examined bone density, bone turnover, and hormonal parameters. Girls with AN had lower fat mass, lean body mass, lumbar BMD z-scores, and lumbar bone mineral apparent density than controls. OPG levels were higher in girls with AN than in controls (44.5 ± 22.5 pg/ml vs. 34.5 ± 12.7 pg/ml, P = 0.02). Osteocalcin, deoxypyridinoline, estradiol, free testosterone, IGF-I, and leptin were lower in AN than in healthy adolescents. OPG values correlated negatively with body mass index (r = -0.27, P = 0.02), percent fat mass (r = -0.35, P = 0.0002), leptin (r = -0.28, P = 0.02), lumbar BMD z-scores (r = -0.25, P = 0.03), and lumbar bone mineral apparent density (r = -0.26, P = 0.03). In conclusion, adolescent girls with AN have higher serum OPG values than controls. OPG values correlate negatively with markers of nutritional status and lumbar bone density z-scores and may be a compensatory response to the bone loss seen in this population.

This work was supported in part by NIH Grants M01-RR-01066 and DK-52625-05.

Abbreviations: AN, Anorexia nervosa; BA, bone age; BCE, bone collagen equivalent; BMD, bone mineral density; BMI, body mass index; BSAP, bone-specific alkaline phosphatase; CA, chronological age; CV, coefficient of variation; DHEAS, dehydroepiandrosterone sulfate; DPD, deoxypyridinoline; IGFBP, IGF binding protein; LBMAD, lumbar bone mineral apparent density; LBMD, lumbar BMD; NTX, N-telopeptide; OC, osteocalcin; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-{kappa}B; RANKL, RANK ligand.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Galusca, M. Zouch, N. Germain, C. Bossu, D. Frere, F. Lang, M.-H. Lafage-Proust, T. Thomas, L. Vico, and B. Estour
Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 110 - 117.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Misra, K. K. Miller, J. Cord, R. Prabhakaran, D. B. Herzog, M. Goldstein, D. K. Katzman, and A. Klibanski
Relationships between Serum Adipokines, Insulin Levels, and Bone Density in Girls with Anorexia Nervosa
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2046 - 2052.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
G. Mazziotti, G. Amato, F. Sorvillo, M. Piscopo, M. R. Rizzo, E. Lalli, L. Iride, M. Cioffi, A. M. Molinari, G. Paolisso, et al.
Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
Eur. J. Endocrinol., March 1, 2006; 154(3): 373 - 377.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society